The life expectancy of an HIV-infected individual can be effectively prolonged with HAART. However, for what is said to be around one in ten patients, treatment fails to work due to the development of drug resistance. In a combined effort, researchers from Imperial College London (UK), the National Cancer Institute (Bethesda MD, USA) and Innsbruck Medical University carried out a study in the hopes of increasing the susceptibility of these patients to HAART.
展开▼
